A Phase I Dose-Escalation First-In-Human Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral MEK Inhibitor MSC2015103B Administered with (EMR200064-001)Two Different Treatment Schedules in Subjects with Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 10 May 2017
At a glance
- Drugs MSC 2015103B (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors EMD Serono
- 10 Jun 2017 Biomarkers information updated
- 27 Mar 2017 Status changed from completed to discontinued.
- 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.